Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours | MicrobiomeTrials← Back to trialsNCT06345079
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-10-14Est. Completion: 2027-09
Enrollment target: 78 participants Locations- Royal North Shore Hospital, Sydney, New South Wales, Australia
- Wollongong Hospital, Wollongong, New South Wales, Australia
- Royal Brisbane and Womens Hospital, Brisbane, Queensland, Australia
- Cairns Hospital, Cairns, Queensland, Australia
- Toowoomba Hospital, Toowoomba, Queensland, Australia
- The Queen Elizabeth Hospital, Adelaide, South Australia, Australia
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- Kalgoorlie Health Campus, Kalgoorlie-Boulder, Western Australia, Australia
- Fiona Stanley Hospital, Perth, Western Australia, Australia
- Cross Cancer Institute, Edmonton, Alberta, Canada
- BC Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada
- London Health Sciences Centre Research Institute (LHSCRI), London, Ontario, Canada
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- University Health Network Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
Other microbiome trials you might be interested in
Metastatic Melanoma
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined wi…
Los Angeles, United StatesCompleted Nov 2011
Prostate CancerLeukemiaBreast CancerMelanomaColorectal Cancer
Study Description:
ELEA is an observational cohort study that will collect exposure information and biospecimens from t…
Bethesda, United StatesCompleted Dec 23, 2027
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada